Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms

Basit Öğe Kaydı
dc.contributor.authorSoyer, Nur
dc.contributor.authorHaznedaroglu, Ibrahim C.
dc.contributor.authorComert, Melda
dc.contributor.authorCekdemir, Demet
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorUnal, Ali
dc.contributor.authorCagliyan, Gulsum
dc.contributor.authorBilgir, Oktay
dc.contributor.authorIlhan, Osman
dc.contributor.authorOzdemirkiran, Fusun
dc.contributor.authorKaya, Emin
dc.contributor.authorSahin, Fahri
dc.contributor.authorVural, Filiz
dc.contributor.authorSaydam, Güray
dc.date.accessioned2019-10-27T11:22:11Z
dc.date.available2019-10-27T11:22:11Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia-negative malignancies characterized by a clonal proliferation of one or several lineages. The aim of this report was to determine the demographic features, disease characteristics, treatment strategies, and survival rates of patients with CMPNs in Turkey. Materials and Methods: Across all of Turkey, 9 centers were enrolled in the study. We retrospectively evaluated 708 CMPN patients' results including 390 with ET, 213 with PV, and 105 with PMF. Results: The JAK2V617F mutation was found positive in 86% of patients with PV, in 51.5% of patients with ET, and in 50.4% of patients with PMF. Thrombosis and bleeding at diagnosis occurred in 20.6% and 7.5% of PV patients, 15.1% and 9% of ET patients, and 9.5% and 10.4% of PMF patients, respectively. Six hundred and eight patients (85.9%) received cytoreductive therapy. The most commonly used drug was hydroxyurea (89.6%). Leukemic and fibrotic transformations occurred at rates of 0.6% and 13.2%. The estimated overall survival in PV, ET, and PMF patients was 89.7%, 85%, and 82.5% at 10 years, respectively. There were no significant differences between survival in ET, PV, and PMF patients at 10 years. Conclusion: Our patients' results are generally compatible with the literature findings, except for the relatively high survival rate in PMF patients. Hydroxyurea was the most commonly used cytoreductive therapy. Our study reflects the demographic features, patient characteristics, treatments, and survival rates of Turkish CMPN patients.en_US
dc.identifier.doi10.4274/tjh.2016.0005
dc.identifier.endpage33en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1en_US
dc.identifier.pmid27094252en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.2016.0005
dc.identifier.urihttps://hdl.handle.net/11454/33005
dc.identifier.volume34en_US
dc.identifier.wosWOS:000398059500004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic myeloproliferative neoplasmsen_US
dc.subjectTreatmenten_US
dc.subjectSurvivalen_US
dc.subjectJAK2 mutationen_US
dc.titleMulticenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasmsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu